S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.04
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IMPL stock logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.


IMPL Stock News Headlines

Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN?
Financial giants have been injecting millions into the crypto market. The big players are going all in on crypto… but what are they gearing up for? There is a significant event on the horizon that will shape the future of Bitcoin—the upcoming Bitcoin halving event…We're revealing all the secrets behind the financial elite's bold moves in crypto during our LIVE, online event.
Impel Pharmaceuticals (IMPL) Receives a Hold from JonesTrading
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN?
Financial giants have been injecting millions into the crypto market. The big players are going all in on crypto… but what are they gearing up for? There is a significant event on the horizon that will shape the future of Bitcoin—the upcoming Bitcoin halving event…We're revealing all the secrets behind the financial elite's bold moves in crypto during our LIVE, online event.
Biotech Catches Major Premarket Bid
84P.SG - Impel Pharmaceuticals Inc
Impel Pharmaceuticals Inc. (IMPL)
Impel Pharmaceuticals gets new CFO
See More Headlines
Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/24/2024
Next Earnings (Estimated)
3/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Net Income
$-106,310,000.00
Net Margins
-353.93%
Pretax Margin
-353.93%

Debt

Sales & Book Value

Annual Sales
$20.99 million
Book Value
($1.86) per share

Miscellaneous

Free Float
22,418,000
Market Cap
$956,000.00
Optionable
Not Optionable
Beta
1.17
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Leonard S. Paolillo (Age 44)
    Interim President & CEO
    Comp: $523.97k
  • Dr. John D. Hoekman Ph.D. (Age 42)
    Co-Founder and Chief Technology & Development Officer
  • Mr. Michael W. Kalb CPA (Age 52)
    Chief Financial Officer
  • Ms. Jennifer L. Berman
    Vice President of Marketing
  • Ms. Sarah Wille
    Vice President of Human Resources
  • Dr. Lynn C. Gold Ph.D. (Age 66)
    Senior Vice President of Regulatory
  • Mr. Scott Youmans (Age 56)
    Senior Vice President of Technical Operations














IMPL Stock Analysis - Frequently Asked Questions

When is Impel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our IMPL earnings forecast
.

How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.42. The business earned $0.09 million during the quarter.

When did Impel Pharmaceuticals IPO?

(IMPL) raised $80 million in an IPO on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

This page (NASDAQ:IMPL) was last updated on 2/25/2024 by MarketBeat.com Staff